NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis $6.14 -0.04 (-0.65%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$6.30 +0.16 (+2.52%) As of 08/7/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImmuCell Stock (NASDAQ:ICCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuCell alerts:Sign Up Key Stats Today's Range$6.14▼$6.2150-Day Range$6.00▼$7.6052-Week Range$3.34▼$7.60Volume3,496 shsAverage Volume15,814 shsMarket Capitalization$55.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Read More ImmuCell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreICCC MarketRank™: ImmuCell scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ImmuCell. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is -87.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is -87.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuCell has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ImmuCell's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.33% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.33% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently increased by 38.13%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ImmuCell this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of ImmuCell is held by insiders.Percentage Held by InstitutionsOnly 13.47% of the stock of ImmuCell is held by institutions.Read more about ImmuCell's insider trading history. Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Email Address ICCC Stock News HeadlinesImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025August 7 at 8:00 AM | globenewswire.comImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025July 9, 2025 | globenewswire.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live. | Priority Gold (Ad)ImmuCell Embarks on CEO Succession Planning ProcessJune 25, 2025 | globenewswire.comImmuCell stock soars to 52-week high, touches $7 markJune 5, 2025 | investing.comImmuCell to Hold Virtual-Only Annual Meeting of StockholdersJune 5, 2025 | globenewswire.comImmuCell Q2 2025 slides: sales momentum continues as Re-Tain awaits FDA approvalMay 16, 2025 | investing.comEarnings call transcript: ImmuCell’s Q1 2025 revenue hits record, stock surgesMay 16, 2025 | investing.comSee More Headlines ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed this year? ImmuCell's stock was trading at $5.15 at the beginning of the year. Since then, ICCC stock has increased by 19.2% and is now trading at $6.14. How were ImmuCell's earnings last quarter? ImmuCell Corporation (NASDAQ:ICCC) released its earnings results on Wednesday, May, 14th. The biotechnology company reported $0.16 EPS for the quarter. The biotechnology company had revenue of $8.07 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 1.02% and a negative net margin of 1.00%. Read the conference call transcript. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE). Company Calendar Last Earnings5/14/2025Today8/08/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ICCC CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.16 million Net Margins-1.00% Pretax Margin-0.96% Return on Equity-1.02% Return on Assets-0.61% Debt Debt-to-Equity Ratio0.30 Current Ratio4.12 Quick Ratio2.21 Sales & Book Value Annual Sales$26.49 million Price / Sales2.10 Cash Flow$0.06 per share Price / Cash Flow96.11 Book Value$3.09 per share Price / Book1.99Miscellaneous Outstanding Shares9,040,000Free Float8,441,000Market Cap$55.51 million OptionableNot Optionable Beta0.30 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ICCC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.